Sprouty negatively regulates receptor tyrosine kinase signals by inhibiting Ras/extracellular signal-regulated kinase (ERK) pathways. Sprouty is downregulated in breast, prostate and liver cancers and appears to function as a tumor suppressor. The role of sprouty in colonic neoplasia, however, has not been investigated. Sprouty-2 protein and mRNA transcripts were significantly upregulated in human colonic adenocarcinomas. Strikingly, the c-Met receptor was also upregulated in tumors with increased sprouty-2. To delineate a potential causal relationship between sprouty-2 and c-Met, K-ras mutant HCT-116 colon cancer cells were transduced with purified TAT-sprouty-2 protein or stably transfected with full-length human sprouty-2 gene. Sprouty-2 upregulation significantly increased cell proliferation by accelerating cell cycle transition. Sprouty-2 transfectants showed strong upregulation of c-Met protein and mRNA transcripts and hepatocyte growth factor-stimulated ERK and Akt phosphorylation and enhanced cell migration and invasion. In contrast, knockdown of c-Met by small interfering RNA (siRNA) significantly decreased cell proliferation, migration and invasion in sprouty-2 transfectants. Further, knockdown of sprouty-2 by siRNA in parental HT-29 and LS-174T colon cancer cells also decreased cell invasion. Sprouty-2 transfectants formed significantly larger tumor xenografts and showed increased proliferation and angiogenesis and suppressed apoptosis. Sprouty-2 tumors metastasized to the liver from cecal orthotopic implants, suggesting that sprouty-2 might also enhance metastatic signals. Thus, in colon cancer sprouty functions as an oncogene and its effects are mediated in part by c-Met upregulation.
Introduction
To date, four mammalian sprouty proteins (sprouty 1-4) have been identified (Hacohen et al., 1998) . Sprouty-2 is ubiquitously expressed, whereas the expression of other sprouty isoforms is organ-and tissuespecific (Su et al., 2002) . Mitogen-activated protein kinase (MAPK) signals from several receptor tyrosine kinases (RTKs) are inhibited by sprouty, including fibroblast growth factor, vascular endothelial growth factor, platelet-derived growth factor and stem cell factor/kit ligand Kim and Bar-Sagi, 2004; Cabrita and Christofori, 2008) . The inhibitory targets of sprouty, however, remain controversial as sprouty may function upstream of Ras or downstream at the level of Raf Hanafusa et al., 2002; Sasaki et al., 2003; Lee, 2006) . Understanding the molecular mechanisms mediating sprouty function is further complicated by the observation that sproutys do not always inhibit MAPK activation. For example, sprouty-1 and -2 not only failed to suppress EGFinduced MAPK activation in endothelial cells, HEK293, CHO and HeLa cells, but, surprisingly, also enhanced activation of this pathway in these cells (Wong et al., 2001; Lim et al., 2002; Rubin et al., 2003) . Thus, sproutys seem to be capable of up-or downregulating MAPK signals, depending on ligand, RTK and the cell context involved.
The expression of sprouty proteins is altered in a number of cancers. Recent reports indicated downregulation of sprouty isoforms in breast, prostate, lung and liver cancer. The genomic localization of sprouty-2 adjacent to a large CpG island led to the hypothesis that aberrant hypermethylation of this region might suppress sprouty-2 transcription in breast cancer (Lo et al., 2004) . Two studies showed downregulation of sprouty-1 and -2 in prostate cancer (Kwabi-Addo et al., 2004; McKie et al., 2005) , while another reported downregulation of sprouty-2 in liver cancer . Similarly, in non-small-cell lung cancer cells, downregulated sprouty-2 increased the proliferation of K-ras mutant (Sutterluty et al., 2007) . Consistent with these findings, overexpression of sprouty-2 in lung epithelial cells inhibited urethane-induced lung tumorigenesis, supporting a tumor suppressor role for sprouty-2 (Minowada and Miller, 2009) . In contrast to these reports, sprouty can also facilitate tumor formation. In this regard, silencing sprouty-2 in H-ras v12-transformed fibroblast inhibited tumor formation in nude mice and colony formation in agarose (Lito et al., 2008) . These growth effects were only observed in Ras-transformed cells. Sprouty-2 overexpression was also reported in melanomas with mutant B-raf and N-ras (Bloethner et al., 2005) .
The role of sprouty-2 has not been investigated in human colon cancer. In this study, we show that sprouty-2 is upregulated in human colon adenocarcinomas. Activating K-ras mutations occur frequently in colon cancers that could theoretically block sprouty inhibition of Ras signals. To test this hypothesis, a K-ras mutant HCT-116 human colon cancer cell line exhibiting minimal levels of sprouty-2 was transduced with purified TAT-sprouty-2 protein or stably transfected with an expression plasmid encoding the full-length protein sequence of the human sprouty-2 gene. Our studies indicate that sprouty-2 upregulation induces c-Met expression. Furthermore, sprouty-2 upregulation enhances the transformed phenotype, as assessed by increased cell proliferation, cell migration and invasion in colon cancer cells. Underscoring the biological relevance of these observations, we found that sprouty-2 transfectants when injected in nude mice produced significantly larger tumors. An orthotopic cecal model of liver metastasis suggested that sprouty-2 upregulation also enhanced competence for liver metastasis. To our knowledge, this is the first study to show sprouty-2 overexpression in human colon cancers and an enhanced cancer phenotype of K-ras-mutated colon cancer cells.
Results

Sprouty-2 upregulation in human colon adenocarcinomas
To determine the potential role of sprouty-2 in human colon adenocarcinomas, we examined sprouty-2 expression levels in colon cancer samples and surrounding normal colon tissues. As shown in Figure 1a , sprouty-2 was overexpressed in 9 of 10 cancer tissues as compared with low levels of sprouty-2 protein in the surrounding normal-appearing colonic mucosa. As assessed by quantitative scanning densitometry, we detected 2-15-fold increases in sprouty-2 expression levels in cancer tissues. Furthermore, sprouty-2 mRNA levels were also analyzed by real-time PCR. A significant increase in sprouty-2 transcripts compared with adjacent normal mucosa was noted (Figure 1b) . In contrast, expression levels of sprouty-1 and -4 isoforms were not changed (data not shown), showing that sprouty-2 might be involved in colorectal carcinogenesis. These tumors were obtained from cecum, and ascending and descending colons. Tumors ranged from moderately to poorly differentiated and showed varying stages of invasion. There was no correlation between the level of sprouty-2 expression and tumor grade.
Increased cell proliferation in Tat-sprouty-2-transduced colon cancer cells To determine the biological growth phenotype induced by human sprouty-2 in colon cancer, we transduced HCT-116 cells with sprouty-2. The addition of an 11-amino-acid sequence from the TAT protein of human immunodeficiency virus to the amino-terminus of a protein induces transport of the fusion protein across cell membranes. As a control, we also transduced colon cancer cells with TAT-green fluorescent protein (GFP) that contained the GFP reporter fused to the TAT protein. As shown in Figure 2a , the transduction efficiency of TAT-fused GFP into HCT-116 cells after 5 h of incubation was nearly 100%. HCT-116 cells were also transduced with TAT-HA-sprouty-2 for different time periods, washed extensively, and cell lysates subjected to western blotting with anti-HA antibody for the presence of TAT-HA-sprouty-2 protein. As shown in Figure 2b , TAT-HA-sprouty-2 protein was detected in cells within 1 h of incubation. Transduced HCT-116 cells were allowed to grow in 2 or 10% fetal Figure 1 Sprouty-2 upregulation in human colon adenocarcinomas. (a) Frozen tissues were homogenized as described in Materials and methods and lysates probed for sprouty-2 expression by western blotting. Blots were re-probed for b-actin as a loading control. Quantitative densitometry values are expressed as fold increases in sprouty-2 expression in colon adenocarcinomas' tumor biopsies (T), compared with adjacent normal-appearing colonic mucosa (N). (b) Total RNA was isolated from six tumors and adjacent normal mucosa. Sprouty-2 mRNA level was quantified as described in Materials and methods. Mean ± s.d. fold change in tumors compared with adjacent normal-appearing colonic mucosa. *Po0.05, compared with normal mucosa. bovine serum-containing media and cell proliferation assessed 48 h later with Wst-1 reagent. Sprouty-2 significantly increased the cell viability in low-serum as well as normal-serum conditions compared with GFPtransduced cells (Figure 2c ).
Sprouty-2 upregulation increases cell proliferation and cell cycle transition
To study sprouty-2-induced growth phenotypic alterations in colon cancer cells, we also transfected HCT-116 cells with cDNA encoding HA-tagged full-length human sprouty-2. We selected several stable monoclonal populations of HCT-116 transfectants with upregulated sprouty-2. We observed 6-29-fold increases in sprouty-2 protein expression ( Figure 3a ) and greater than 70-fold increases in sprouty-2 transcripts (Figure 3b ) by realtime PCR as compared with empty vector (EV) cells. As sprouty-2-transduced colon cancer cells had increased cell proliferation (Figure 2c) , we assessed the effects of sprouty-2 upregulation on cell proliferation. Sprouty-2 transfectants also proliferated significantly faster than EV clones, as assessed by total cell counts obtained using a coulter counter (Figure 3c ) and Wst-1 assay (inset). To assess whether increased cell numbers reflected a change in cell cycle, we measured cell cycle phase distribution at the indicated time points (Table 1) . Cells were serum starved and re-stimulated with 10% serum-containing media. After 8 h of serum stimulation, the cell populations in different phases of cell cycle were comparable in both cell types. At later time points, however, in EV transfectants, a gradual decrease in G 0 -G 1 phases with concomitant increase in G 2 /M phases was observed (Table 1 and Figures 4a-c) . In contrast to EV cells, we observed a rapid decrease in G 2 /M phases and a parallel increase in G 0 -G 1 phases in sprouty-2 transfectants (Table 1 and Figures 4a-c) . These data clearly indicate that after serum stimulation sprouty-2 transfectants cycled faster as compared with EV cells. There were no significant differences (mean±s.d., n ¼ 5) in apoptotic rates between EV (3.6 ± 2.7%) and sprouty-2 transfectants (4.5 ± 2.9%). These results show that the increased viability of sprouty-2 transfectants in normal serum-containing media was due to increased proliferation without affecting the basal rate of apoptosis. We further confirmed the cellular proliferation by incorporating 5-bromo-2-deoxyuridine (BrdU) as a parameter for DNA synthesis. We observed a significant increase in DNA synthesis in sprouty-2 transfectants as compared with EV cells (Figure 4d ). Cell cycle progression is positively regulated by interactions between the cyclindependent kinases and G 1 cyclins and negatively regulated by cyclin kinase inhibitors (Nigg, 1995) . We then demonstrated that cyclin D1 was significantly upregulated in sprouty-2 transfectants compared with EV-transfected cells (Figure 4e) . The roles of G 1 cyclindependent kinase and other G 1 cyclins will require further investigation.
Hepatocyte growth factor augments cell signaling, migration and invasion in sprouty-2 transfectants The regulation of RTK expression and signaling by sprouty-2 has been shown earlier (Lo et al., 2006) . We then investigated whether the altered phenotype of sprouty-2 transfectants was due to the increased RTK expression and activity. We found that c-Met protein and mRNA transcripts were upregulated approximately 10-and 35-fold, respectively, in sprouty-2 transfectants compared with EV transfectants (Figures 5a and b ). In addition, the level of c-Met tyrosine phosphorylation induced by hepatocyte growth factor (HGF) in sprouty-2 clones was three-to fivefold higher than EVtransfected cells (Figure 5c ). These results showed that sprouty-2 induces an increase in functional c-Met in colon cancer cells. The important downstream effectors of c-Met include phosphatidylinositol 3-kinase/Akt and MAPK/extracellular signal-regulated kinase (ERK), which mediate proliferative and pro-survival signals (Kanayama et al., 2007) . In colon cancer cells, Akt and ERK enhance cell cycle progression and inhibit apoptosis (Vaculova et al., 2006) . HGF induced significantly greater time-dependent increases in Akt ( Figure 5d ) and ERK ( Figure 5e ) activations in sprouty-2 transfectants compared with EV transfectants. These data suggest that sprouty-2, at least in part, enhances colon cancer cell growth by upregulating c-Met signaling. The HGF/ c-Met axis has been shown to contribute to colon cancer Figure 3 Sprouty-2 upregulation increases cell proliferation. (a) HCT-116 cells were transfected to express HA-human sprouty-2 as described in Materials and methods. Single clones were selected and screened by western blotting with sprouty-2 (upper panel) and reprobed with b-actin (lower panel) antibodies. EV (empty vector, pHm6) transfectants were control monoclonal populations transfected with EV and selected for G418 resistance. Sprouty-2 expression was expressed as fold of EV. (b) Total RNA was isolated from EV and sprouty-2 transfectants. Sprouty-2 mRNA levels were quantified and expressed as fold of EV cells (mean ± s.d.) as described in 'Materials and methods'. *Po0.05, compared with EV. (c) EV-and sprouty-2-transfected cells were plated in 10% serum-containing medium in six-well plates. Cells were trypsinized and collected at indicated times and counted using a coulter counter. Data represent mean ± s.e. of three independent experiments. *Po0.05, compared with EV controls. Inset, cell proliferation by Wst-1 assay. EV and sprouty-2 transfectants were plated in 96-well microtiter plates. After 48 h of plating, Wst-1 reagent was added and the absorbance was measured at 450 nm as described in 'Materials and methods'. Data represent means±s.e. of three independent experiments. *Po0.05, compared with EV controls. Abbreviations: EV, empty vector; SPRY-2, sprouty-2. EV and SPRY-2 transfectants were analyzed at indicated times using CellQuest software in a FacScan flow cytometer as described in Materials and methods. The distribution of DNA in the cell cycle was determined using Modfit LT software.
cell migration and invasion (Kermorgant et al., 2001) . As functional c-Met was upregulated in sprouty-2 transfectants, we asked whether HGF would increase the migratory and invasive properties of sprouty-2-transfected colon cancer cells. Sprouty-2 upregulation caused a three-to fivefold increase in cell migration ( Figure 5f ) and invasion ( Figure 5g ) as compared with EV cells.
c-Met siRNA decreases cell proliferation, migration and invasion in sprouty-2 transfectants As sprouty-2-transfected colon cancer cells had increased c-Met expression, cell proliferation, migration and invasion, we hypothesized that c-Met downregulation will revert this phenotype in sprouty-2 transfectants. Indeed, small interfering RNA (siRNA)-mediated downregulation of c-Met significantly reduced cell proliferation (Figure 6a ), migration ( Figure 6b ) and invasion ( Figure 6c ).
Sprouty-2 siRNA decreases cell invasion in parental HT-29 and LS-174T cells
To demonstrate that the effect of sprouty-2 upregulation is not specific to HCT-116 cells, which are mutated for K-ras, we utilized two other colon cancer cell lines, HT-29 wild-type for K-ras and LS-174T mutated for K-ras. Downregulation of constitutive sprouty-2 by siRNA in these cell lines significantly inhibited cell invasion ( Figure 6d ). These results show that the effect of sprouty-2 in colon cancer cells is not K-ras mutation specific or limited to a unique cell type.
c-Met upregulation in human colon adenocarcinomas As sprouty-2 transfectants had increased c-Met expression, we next asked whether human tumors that express higher levels of sprouty-2 (Figure 1 ) would also show an upregulation of c-Met receptor. We showed that c-Met was over-expressed in 11 of 12 cancer tissues as compared with low levels of c-Met protein in adjacent normalappearing colonic mucosa (Figure 7a ). Levels of c-Met over-expression ranged from 2-to 28-fold in cancer tissue. Furthermore, c-Met mRNA transcripts were increased by more than 50-fold in these colonic tumors, as compared with normal colonic mucosa (Figure 7b ).
Increased proliferation, angiogenesis and decreased apoptosis in sprouty-2 xenografts To evaluate the oncogenic potential of sprouty-2 in vivo, we examined tumor xenograft growth of EV or In agreement with this, the proliferation marker Ki-67 was fivefold greater in sprouty-2 tumors compared with EV tumors (Figures 9A and B) . However, we also observed a significant decrease in expression of cleaved caspase-3 (active caspase-3) in sprouty-2 tumors compared with EV tumors (Figures 9A and C) . Caspase-3 is a key effector caspase in the apoptosis pathway, amplifying signals from initiator caspases, such as caspase-8 (Huerta et al., 2006) . A decrease in apoptosis as assessed by lower cleaved caspase-3 levels in sprouty-2 tumors would also be expected to contribute to the increased size of these tumors compared with EV tumors. Neoangiogenesis is an important requirement for tumor growth. As sprouty-2 tumors were significantly larger than EV tumors, we assessed tumor vascularization. Nestin-1, a class VI intermediate filament protein, is a novel angiogenesis marker used to detect newly proliferating endothelial cells in colorectal angiogenesis (Teranishi et al., 2007) . As assessed by quantitative nestin-1 immunostaining ( Figure 9A ), there was a fivefold increase in mean vessel area ( Figure 9D ) and a fourfold increase in total number of vessels ( Figure 9E ) in sprouty-2 tumors compared with EV tumors.
Prostaglandins are important mediators of neoplastic capillary growth (Wang et al., 2008) . As cyclooxygenase-2 (Cox-2) is the rate-limiting enzyme in prostaglandin biosynthesis and is frequently upregulated in colon cancer, we measured expression of this enzyme ( Khare et al., 2003 Khare et al., , 2008 Harris, 2009 ). Cox-2 levels were significantly higher in most sprouty-2 tumors compared with EV tumors (Figure 9F ), consistent with the increased angiogenesis noted.
Increased liver metastasis arising from cecal orthotopic sprouty-2 HCT-116 tumor xenografts As sprouty-2 enhanced the growth phenotype of colon cancer cells in culture and in tumor xenografts in vivo, we asked whether upregulation of c-Met by sprouty-2 would influence the metastatic potential of these cells. We implanted a small piece of a tumor derived from EV or sprouty-2 xenografts into the cecal wall of nude mice. Tumor fractions with equal size and weight were implanted into each mouse. After 8 weeks, mice were killed and livers were harvested. Tissues were fixed in formalin and stained with hematoxylin and eosin. Three of four sprouty-2 tumors developed liver metastases compared with only one EV tumor. A representative liver section showing metastatic sprouty-2 cells is shown in Figure 9G . These results strongly suggest that sprouty increases the metastatic potential of K-ras mutant colon cancer cells. Lee et al., 2004; Poppleton et al., 2004) . Sprouty proteins act as competitive inhibitors and have been shown to block the Ras/MAPK pathway at multiple levels extending from RTK to Raf activation. All sprouty proteins share a highly conserved cysteine-rich domain at the carboxy-terminus. This domain is believed to be critical to target sprouty to the plasma membrane, in which it can inhibit MAPK signals (Yigzaw et al., 2001; Hanafusa et al., 2002; Lim et al., 2002) . The carboxy-termini of sprouty-2 and -4 can bind directly to Raf-1, inhibiting Raf-1 kinase activity (Sasaki et al., 2003) . In contrast, in certain mammalian contexts, sprouty proteins not only fail to inhibit, but may even potentiate epidermal growth factor receptor (EGFR) signals (Impagnatiello et al., 2001; Egan et al., 2002; Lim et al., 2002; Hall et al., 2003; Pelletier et al., 2003; Sasaki et al., 2003) . Previous reports have provided experimental evidence that the amino-terminal tyrosine residue of sprouty-2, Tyr 55 , functions as a docking site for the SH2 domain of c-Cbl (Fong et al., 2003; Hall et al., 2003; Pelletier et al., 2003) . Sprouty-2 can compete with EGFR for binding to c-Cbl and thereby block EGFR ubiquitination and degradation (Fang et al., 1999; Egan et al., 2002; Lim et al., 2002) . As a consequence, EGFR fails to downregulate and can promote sustained activation of the MAPK pathway (Fang et al., 1999; Egan et al., 2002; Lim et al., 2002) . Specifically, in Ras-transformed fibroblasts, sprouty-2 sustains the level and signaling activity of EGFR and is necessary for tumor formation (Lito et al., 2008) . In addition, sprouty-1 and -2 uncouple RTK Figure 8 Sprouty-2 upregulation increases tumor xenograft growth in BALB/c-nu/nu mice. Empty vector (EV) or sprouty-2 transfectants were injected into the flanks of nude mice (five mice in each group). Tumor size was measured every week, and on day 28 tumors were excised as described in Materials and methods. Significant increases in sprouty-2 transfectant tumor sizes were detected on days 14, 21 and 28 compared with time-matched EV tumors. *Po0.05, compared with mice injected with EV-transfected cells. Inset, sprouty-2 upregulation significantly increases tumor weight compared with EV tumors (day 28). *Po0.05, compared with tumors from mice injected with EV transfectants.
Sprouty and colon cancer
C Holgren et al signaling from Ras activation, possibly by sequestering Grb-2, an adaptor protein required for Ras activation (Brett et al., 2001; Hanafusa et al., 2002) . The roles of sprouty proteins, however, have never been investigated in colon cancer. In our studies, sprouty-2 upregulation in K-ras mutant HCT-116 colon cancer cells enhanced cell proliferation, migration and invasion. Furthermore, the RTK c-Met was upregulated in sprouty-2 transfectants. Future studies will be required to elucidate how sprouty-2 increases c-Met expression in colon cancer cells. Sprouty-2 might increase synthesis by stimulating c-Met transcription or decrease degradation, as Cbl-dependent receptor ubiquitination and degradation by the proteasomal/ lysosomal pathways also regulate c-Met expression (Li et al., 2007) .
Sprouty-2 inhibited proliferation and migration of HeLa cells (Yigzaw et al., 2001 ) and human umbilical vein endothelial cells (Impagnatiello et al., 2001 ) in response to a number of growth factor receptor agonists. Similarly, sprouty-2 was shown to inhibit proliferation of NIH3T3 cells ) and rat intestinal epithelial cells (Poppleton et al., 2004) by suppressing Ras activation. In contrast, in this study we showed for the first time that sprouty-2 upregulation in HCT-116 colon cancer cells increased cell proliferation and enhanced HGF-induced invasion and migration. The underlying mechanisms that mediate increased proliferation and enhanced migration will require further study, but appear to involve c-Met upregulation. Alternatively, sprouty-2 might drive both inhibitory signals by inhibiting the Ras pathway and activating Figure 9 Sprouty-2 upregulation increases cell proliferation, survival, angiogenesis in tumor xenografts and increases the liver metastasis of cecal implants. (A) c-Met, Ki-67 (proliferation marker), cleaved caspase-3 (apoptosis marker) and nestin-1 (endothelial cell angiogenesis marker) immunostaining in sprouty-2 and EV tumor xenografts. Computer-assisted quantitation for Ki-67 (B), cleaved caspase-3 (C), mean blood vessel area/field (D) and total vessels per field (E) in tumor xenografts. *Po0.05, compared with EV tumors. (F) Sprouty-2 increases Cox-2 expression in tumor xenografts. Tumor lysates from EV and sprouty-2 groups were probed for Cox-2 by western blotting. Blots were re-probed for b-actin as a loading control. (G) Tumor fragments (4 mm, 75 mg) taken from subcutaneously growing tumor xenografts were implanted in the cecal wall as described in Materials and methods. After 8 weeks, livers were harvested and sections stained with hematoxylin and eosin. Shown are representative liver metastasis magnified Â 100 and Â 200 in a mouse implanted with subcutaneous sprouty-2 tumor fragment. Four implantations were carried out in each group. Three out of four tumors in the sprouty group showed liver metastasis, whereas only one tumor in EV group showed metastatic lesion. signals by other pathways (c-Met, for example). The presence of Ras mutations might circumvent the inhibitory effects, allowing the stimulatory signals to be dominant. Sprouty-2 knockdown by siRNA in K-ras wild-type HT-29 and K-ras mutated LS-174T cells significantly reduced cell invasion, indicating that the oncogenic effects of sprouty-2 in colon cancer cells are not K-ras dependent or unique to one specific cell type.
Metastatic disease is the major cause of colon cancerrelated death. For this reason, identifying individuals with stage II or III locally resectable disease, who are at increased risk for metastasis is of great importance. Our studies suggest that sprouty-2 upregulation increases the risk of cells forming metastasis. In part, c-Met upregulation by sprouty-2 might account for this increased metastatic potential, as c-Met is known to increase proliferation, migration and invasion (Corps et al., 1997; Nakanishi et al., 1999; Kermorgant et al., 2001) . In tumor cells, c-Met can be activated in a ligandindependent manner through c-Met mutation, overexpression and amplification (Trusolino and Comoglio, 2002) . Recent studies have failed to find c-Met mutations in colon cancer (Zeng et al., 2008) . Several studies indicate, however, that c-Met over-expression contributes to invasion and metastasis, and that overexpression was significantly associated with increased risk for local invasion and lymph-node metastasis (Fujita and Sugano, 1997; Schmidt et al., 1999; Takeuchi et al., 2003; Zeng et al., 2004; Kammula et al., 2007) . Further studies are needed to dissect how sprouty-2 upregulates c-Met in colon cancer. It will also be of interest to examine sprouty-2 expression levels in other tumor types with elevated c-Met expression. Thus, in colon cancer sprouty-2 over-expression enhances the transformed phenotype and its effects are mediated in part by c-Met up-regulation.
Materials and methods
Human colonic tumors
This study was approved by the University of Chicago Hospitals Institutional Review Board for human investigations. Specimens included colon cancer samples and paired adjacent normal-appearing colonic mucosa. Tumors were divided and a portion fixed in 10% buffered formalin for histological classification. Another fraction was flash frozen in liquid nitrogen and stored at À80 1C until analysis. Tumor histology was graded by an expert gastrointestinal pathologist (Dr John Hart, University of Chicago, Chicago, IL, USA). For western blotting experiments, frozen tissues were homogenized with a Polytron. Tissues were then sonicated and proteins solubilized in sodium dodecyl sulfate-Laemmli buffer.
Plasmid constructs and TAT proteins
Full-length human sprouty-2 cDNA was subcloned into the Kpn1/EcoR1 sites of HA-tag-encoded mammalian expression vector pHM6 (Roche Molecular Biochemicals, Indianapolis, IN, USA) as described (Yigzaw et al., 2001) . TAT-GFP and TAT-HA-human sprouty-2 purified proteins were prepared as described earlier (Edwin et al., 2006) . The TAT-HA tag includes an amino-terminal hexahistidyl leader followed by the 11-amino-acid TAT protein transduction domain (YGRKKRRQRRR) and an HA tag (YPYDVPDYA). The TAT-HA bacterial expression vector and purification of TAT-GFP and TAT-HA-human sprouty-2 proteins were described previously (Yigzaw et al., 2001) .
Cell culture
Human HCT-116 colon cancer cells were obtained from American Type Culture Collection and grown in Dulbecco's modied Eagle's medium (Mediatech, Inc., Manassas, VA, USA) supplemented with 10% fetal bovine serum (Hyclone, Thermo Scientific, Waltham, MA, USA) and penicillinstreptomycin mixture (Mediatech). HCT-116 cells express mutant K-ras, but low levels of sprouty-2 compared with other colon cancer cell lines (data not shown).
Selection of stable clones HCT-116 cells (100 000 cells per well, six-well plates) were plated into McCoy's 5A medium containing 10% serum. The following day, cells were transfected with plasmid construct encoding HA-human sprouty-2 or vector alone using the Effectene transfection reagent (Qiagen, Valencia, CA, USA). After 24 h, the media was supplemented with the antibiotic Geneticin (G418) (Mediatech, Inc.) at 800 mg/ml. Individual G418-resistant clones were isolated and expanded and maintained in 800 mg/ml G418. Expression of HA-human sprouty-2 was confirmed by western blotting.
Western blotting
Cells were homogenized in Laemmli buffer and proteins quantified by BioRad RC-DC assay. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blots were incubated overnight at 4 1C with specific primary antibodies, including b-actin (1:10 000; Sigma-Aldrich, St Louis, MO, USA), phospho-ERK1,2 (1:2500; Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA), phospho-AKTser473 (1:2000; Cell Signaling, Danvers, MA, USA), total ERK (1:3000; Cell Signaling), total AKT (1:3000; Cell Signaling), sprouty-2 (1:3000; Sigma-Aldrich), c-Met (1:1000; Santa Cruz Biotechnology, Inc), Cox-2 (1:1000; Cayman Chemical, Ann Arbor, MI, USA), cyclin D1 (1:10 000; Santa Cruz Biotechnology, Inc) and HA-tag (1:5000; Cell Signaling), followed by 1 h incubation with appropriate peroxidase-coupled secondary antibodies (Santa Cruz Biotechnology, Inc) and detection with enhanced chemiluminescence (Pierce, Rockford, IL, USA). Xerograms were digitized by an Epson Expression 1680 flat bed scanner (Long Beach, CA, USA) and captured in Adobe Photoshop. Band densitometry was quantified using IP Lab Gel software from Scanalytics (Rockville, MD, USA) running on a G4 Apple Macintosh computer. Western blotting band intensities were expressed in arbitrary units and normalized to fold increases compared with control.
Sprouty-2 and c-Met knockdown with siRNA Small interfering RNA transfections were carried out as recommended by the manufacturer (Santa Cruz). Cells were plated (200 000 cells per well, six-well plates) in 10% serum overnight and transfected with 60 pmol control siRNA (an irrelevant control sequence, sc-37007) or sprouty-2 siRNA (sc-41037) or c-Met siRNA (sc-29397) for 6 h. Cells were allowed to grow for 48 h and lysates were tested by western blotting.
Cell proliferation
For Wst-1 and BrdU assays, cells were plated in 10% serumcontaining media in 96-well plates (10 000 cells per well). Cell growth was assessed by a Wst-1 cell proliferation assay kit (Cayman Chemical) and enzyme-linked immunosorbent assay for BrdU incorporation into cellular DNA by a labeling and detection kit (Roche Molecular Biochemicals). Further, cells were also plated in six-well plates (100 000 cells per well) for the indicated times, trypsinized and counted using a coulter counter.
Real-time PCR RNA samples were tested by Agilent chip (Agilent Technologies, Santa Clara, CA, USA) for RNA purity and quantified by RiboGreen. RNA (100 ng) was reverse transcribed into cDNA using the SuperScript III Platinum Two-Step qRT-PCR kit (Invitrogen, Carlsbad, CA, USA) as described earlier (Dougherty et al., 2009) . The resulting first-strand cDNA was used as template for quantitative PCR in triplicate using SYBR Green QPCR Master Mix kit (Applied Biosystems, Carlsbad, CA, USA). Oligonucleotide PCR primer pairs were designed to cross intron-exon boundaries from published mouse sequences in the GenBank database using Primer3 (Rozen and Skaletsky, 2000) . The sprouty-2 primers were forward, 5 0 -AGGGGTTGGTGCAAAGCCGC-3 0 and reverse, 5 0 -GCGACCCGTTGCCACTCTGA-3 0 ; and the c-Met primers were forward, 5 0 -CATTTCCAGTCCTGCAGTCA-3 0 and reverse, 5 0 -CTCCTTCAAGGGGTCCACTA-3 0 . PCR amplification was verified by melting curve and electrophoretic analysis of the PCR products on 3% agarose gel. Negative controls (no reverse transcriptase and no template) yielded no products. The data were analyzed using the comparative DDC t method, and mRNA abundance was normalized to b-actin mRNA and expressed as fold control (Yuan et al., 2006) .
Cell cycle analysis and apoptosis determination
For cell cycle analysis and apoptosis assay (sub-G 0 phase analysis), cells were plated (200 000 cells per well) in six-well plates for 24 h. Cells were synchronized by serum deprivation and then re-stimulated with normal 10% serum-containing media for the desired time periods. Cells were then trypsinized, fixed with 70% ethanol overnight and then stained with propidium iodide solution (10 mg/ml) (Invitrogen) containing RNase A (10 U/ml) (Promega, Madison, WI, USA) at 4 1C for 30 min. The distribution of cells in the cell cycle was assessed by a flow cytometer (Cerda et al., 2001) .
Cell migration and invasion
For cell migration and invasion assays, cells in 1% serumcontaining media were plated onto 8-mm transwell-permeable supports (Corning Inc., Corning, NY, USA) or on BD matrigel transwell invasion chambers, respectively. For migration assays, the lower chamber contained 1% serum-containing media and 5 ng/ml of HGF. Cells were allowed to migrate for 16 h. In invasion assays, the lower chamber contained 1% serum-containing media and 1 ng/ml of HGF. Cells were allowed to invade for 48 h. After incubation, media fractions were discarded and adherent non-invaded cells on the upper surface of the filters were removed with a cotton swab. The filter membranes, containing invaded cells on the lower surface, were cut out and cells fixed in methanol. Cells were stained with Diff Quick Stain Kit (IMEB Inc., San Marcos, CA, USA) and counted under a microscope.
HCT-116 tumor xenografts in BALB/c (nu/nu) mice To assess the effect of sprouty-2 upregulation on HCT-116 tumor xenograft growth, sprouty-2 and EV transfectants (5 Â 10 6 cells) were suspended in 100 ml phosphate-buffered saline and injected subcutaneously in the flank of male nude mice (BALB/c (nu/nu), 4 weeks old). Tumor size was measured weekly using a vernier caliper and the tumor volumes calculated using the formula (a Â b 2 Â 0.5), where a and b represent the larger and smaller diameters, respectively. Tumors were excised after 4 weeks and aliquots fixed in 10% buffered formalin for histology and immunostaining and separate aliquots frozen for western blotting analyses.
Immunostaining Sections, of 5 mm thickness, of formalin-fixed paraffinembedded tumors were cut and mounted on Vectabondcoated Superfrost Plus slides and immunostained as described earlier (Khare et al., 2003 (Khare et al., , 2008 . They were incubated at 4 1C with primary antibodies overnight (c-Met, 1:75; Ki-67, 1:50; cleaved caspase-3, 1:25; and nestin-1, 1:50), followed by incubation with horse radish peroxidase-conjugated secondary antibodies (1:200) at room temperature for 30 min. Antigenantibody complexes were detected using the DAKO EnVision Plus System (Carpinteria, CA, USA) and horseradish peroxidase, using 3,3 0 -diaminobenzidine as substrate. For negative controls, sections were incubated with isotype-matched irrelevant antibodies.
Orthotopic cecal implantation of tumors in nu/nu mice To assess the local invasion and metastatic potential of sprouty-2 upregulated HCT-116 cells, we performed cecal orthotopic tumor implantations (Shoji et al., 2003) . Mice were anesthetized with ketamine (70 mg per kg body weight) and xylazine (7 mg per kg body weight). Subcutaneously growing colon tumors (taken from subcutaneous xenograft studies) were resected aseptically and minced. Aliquots weighing 75 mg (4 mm diameter) were implanted in the cecum. Briefly, an incision was made through the left lower abdominal pararectal line and peritoneum. The cecal wall was exposed and a part of the serosal membrane was scraped with a 27-gauge needle. Care was exercised to prevent the rupture of the cecal wall. A tumor fragment was placed in a serosal pocket that was secured with a transmural suture. The cecum was returned into the peritoneal cavity, and the abdominal wall closed with sutures. The mice were killed 8 weeks after tumor implantation or earlier if they developed signs of distress. At the time of killing, livers were processed for hematoxylin and eosin staining and histological examination.
Statistical analysis
Results are expressed as means±s.d. or means±s.e. as indicated. Data were analyzed using Student's t-test for unpaired samples or analysis of variance as appropriate. Values of Po0.05 were considered statistically significant.
